Lanreotide


Synthetic cyclic octapeptide somatostatin analog with preferential somatostatin receptor subtype 2 and 5 agonism

A cyclic octapeptide somatostatin analog developed by Beaufour-Ipsen as the second clinically available long-acting somatostatin receptor ligand, distinguished by a unique self-assembling supersaturated depot formulation, antiproliferative activity in gastroenteropancreatic neuroendocrine tumors demonstrated in the landmark CLARINET trial, and a three-indication regulatory portfolio spanning acromegaly, neuroendocrine tumor growth control, and carcinoid syndrome.

Abstract

Lanreotide (D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; CAS 108736-35-2 free base; molecular formula C54H69N11O10S2; molecular weight 1096.33) is a synthetic cyclic octapeptide analog of native somatostatin-14, developed by Beaufour-Ipsen (now Ipsen) and introduced clinically in the early 1990s as the second somatostatin analog to reach the market after octreotide. The compound exhibits high-affinity agonism at somatostatin receptor subtypes 2 and 5 (SSTR2, Ki approximately 0.54 to 0.75 nM; SSTR5, Ki approximately 5.2 nM) with moderate affinity at SSTR3 and low affinity at SSTR1 and SSTR4, a selectivity profile that mediates suppression of growth hormone, insulin-like growth factor 1, and multiple gastrointestinal and pancreatic hormones through inhibition of adenylyl cyclase and reduction of intracellular cyclic adenosine monophosphate [1, 2]. The Autogel formulation, first approved in Europe in 2001 and in the United States in 2007, was the first marketed sustained-release pharmaceutical product produced by peptide self-assembly rather than by polymer microsphere encapsulation. Three indications are registered in the United States: long-term treatment of acromegaly in patients who have had an inadequate response to or cannot be treated with surgery and radiotherapy (FDA approved August 2007); treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival (FDA approved December 2014, on the basis of the CLARINET trial); and treatment of carcinoid syndrome in adults to reduce the frequency of rescue somatostatin analog therapy (FDA approved February 2018, on the basis of the ELECT trial) [5, 6, 7]. The principal adverse events at registered doses are gastrointestinal (diarrhea 26 to 65 percent, abdominal pain 7 to 34 percent, nausea 5 to 11 percent), cholelithiasis and gallbladder sludge (14 to 20 percent), injection site reactions (5 to 22 percent), dysglycemia (hyperglycemia 5 to 14 percent, hypoglycemia 2 to 7 percent), and sinus bradycardia (3 to 8 percent) [10]. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph